SUPPORTED BY

**NIHR** National Institute for Health Research



#### <u>POINT OF CARE TESTING USING FEBRIDX</u> ® TO IMPROVE ANTIBIOTIC USE FOR RESPIRATORY TRACT INFECTIONS IN PRIMARY CARE:

# A MIXED METHODS FEASIBILITY STUDY PROTOCOL (PREFIX)

Christopher Wilcox<sup>1</sup>, Nour Odeh<sup>1</sup>, Ingrid Muller<sup>1</sup>, Jill Rutter<sup>1</sup>, Paul Little<sup>1</sup>, Taeko Becque<sup>1</sup>, Nazrul Islam<sup>1</sup>, Tristan Clark<sup>2,</sup> Nick Francis<sup>1</sup>

1: Primary Care Research Centre, University of Southampton

2: School of Clinical and Experimental Sciences, University of Southampton

## POINT OF CARE TESTING

- There is a drive to safely reducing unnecessary antibiotic prescriptions for lower respiratory tract infections (LRTIs) in primary care
- Differentiating viral vs bacterial LRTIs can be challenging
- A promising area is 'point-of-care' testing (POCT) using rapid diagnostic tests
- Current devices mostly limited to single biomarkers (e.g. CRP) or specific pathogens (e.g. influenza) and require large desktop analyzers

# FebriDx®

- FebriDx ® is a single-use, dual-marker, lateral flow test that tests for viral and bacterial host response using a fingerpick of blood and gives a result in 10 minutes
- It identifies immune responses associated with both bacterial infection (C-Reactive Protein CRP) and viral infection (Myxovirus resitance protein A - MxA)
- Costs around £12.75 per test





### FebriDx®



### STUDIES OF FebriDx®

- Nearly all studies based in secondary care
- For bacterial detection, agreement between FebriDx ® and gold-standard PCR was **91.7%** (sensitivity 80%, specificity **93%**) and for viral detection agreement was **84%** (sensitivity 87%, specificity **83%**).
- Has been rolled out in some centres internationally (including Southampton General Hospital ED)
- To-date only one small study in primary care showing good ease-of-use and cost-effectiveness

Self W, et al. 2017 Shapiro NI et al 2018 Sambursky R et al 2015 Clark TW et al 2020

#### AIMS OF OUR FEASIBILITY STUDY

I) Explore the potential clinical utility and facilitators/barriers to using FebriDx ® to safely reduce the use of antibiotics for LRTI in primary care.

2) Explore the feasibility of conducting a future trial assessing the clinical impact, safety and cost-effectiveness of FebriDx ® to guide antibiotic use for LRTIs in UK primary care

## STUDY DESIGN

• Mixed-methods, multi-centre, feasibility study of up to 300 patients at GP practices in South England

STAGE ONE (quantitative data collection)

- P: Patients aged >1 year, with symptoms of a LRTI (<28 days), deemed <u>likely</u> to be prescribed antibiotics (immediate or delayed)
- I: FebriDx
- C: N/A
- O: Outcomes include FebriDx results and success rate, time-to-result, antibiotic use, and subsequent re-consultation/antibiotic use and complications

STAGE TWO (qualitative semi-structured interviews)

• 10-20 patients and 10-20 staff

### INITIAL RESULTS FROM FIRST 38 PATIENTS

FebriDx results

- 60% were negative (i.e. no detection of CRP or MxA)
- 10% both CRP and MxA positive
- 25% positive CRP alone
- 5% positive MxA alone
- Approximate reduction in antibiotic use of around 50% (not including any re-consultation data)
- Clinicians felt more confident that:
  - Antibiotics were <u>not</u> necessary in 50% of cases
  - Antibiotics were necessary in 42%
  - No difference in 8%

## INITIAL RESULTS – QUALITATIVE

Three interviews with patients

- Overall positive about the test found it painless and happy to wait for results
- One patient (had a negative test result) felt the results weren't well explained and left feeling confused and unsatisfied

I think it's definitely a way forward. I come from the business world and I can see speed and efficiency and time saving and cost saving, so I think it's fantastic. Patient 001-004

#### Early feedback from GP practice staff

- Enthusiastic about the test
- There is definitely a learning curve
- Some confusion about the interpretation of a negative result